asco@alo33:162123 JSONTXT

Background: Neoadjuvant chemotherapy NACT folloed by chemoradiation CTRT is hypothesized to improve survival in locally advanced cervical cancer LACC by reducing distant metastasis. Implication of epithelial groth factor receptor EGFR expression and maintenance gefitinib in cervical cancer has not been addressed. The study as aimed to evaluate NACT folloed by CTRT and maintenance gefitinib in LACC. Methods: This as a phase II single arm study. 25 patients pts of LACC ere enrolled beteen July 2012 and May 2013. All patients received 6 eekly doses of Paclitaxel 60mgm-2 and Carboplatin AUC 2 , folloed by CTRT external beam radiotherapy 50.4Gy28fractions5.5 eeks ith concurrent Cisplatin 40 mgm2 and brachytherapy 7 GyX3 eekly fraction . EGFR expression as evaluated by immunohistochemistry. Maintenance gefitinib as advised for 1 year. Toxicity as graded according to the common terminology criteria for adverse events version 4.0. The study as approved by the institute ethics committee. Results: 25 patients of LACC ere enrolled ith median age 47 years range 32 - 60 . 14 patients stage ere IIIB and 11 patients belonged to stage IIB. 24 pts completed the NACT and CTRT and ere started on gefitinib maintenance therapy. 20 patients completed intended the treatment . Median follo up as 27 months range 4-37 . Response rate [partial and complete] to NACT and CTRT as 96 percent.EGFR as moderately or strongly expressed in 86.3 percent of the pts. Age, hemoglobin, lymph node, and tumor size had no statistically significant association ith treatment outcome. 12 pts 50 percent developed grade II diarrhea, 3 12 percent developed III diarrhea needing treatment break. Grade II skin reaction as observed in ten patients 41.6 percent . No significant correlation as demonstrated beteen the expression of EGFR and response to treatment. 64 percent of patients ere in complete remission at the last follo up. Conclusions: NACT folloed by CTRT is associated ith high initial response rate in LACC. Gefitinib as maintenance therapy is ell tolerated.,J Clin Oncol 34, 2016 suppl; abstr e17014 ,Publication Only Gynecologic Cancer